Navigation Links
Using Public Relations to Launch, Grow, and Extend Pharmaceutical and Biotech Brands
Date:8/30/2011

CHAPEL HILL, N.C., Aug. 30, 2011 /PRNewswire/ -- Savvier consumers and competition from generic drugs have made commercial success, whether at market entry or during brand maturity, more elusive.  At the same time, new technologies have greatly expanded the ability of cost-efficient Public Relations to support pharmaceutical brand growth.

While biopharma marketers have long used Public Relations to support their brands, recent field research from Best Practices, LLC suggests few companies have utilized the full potential of PR campaigns across the entire product lifecycle – preparing, launching, growing and extending the commercial life of a brand.  New technologies and market changes have greatly expanded the reach and potential of cost-efficient PR through Web sites, online social networks, blogs, and traditional media sources.

According to the study, the lifecycle phases that showed the most effective and active use of PR tactics are the pre-launch, launch and brand-building years.  Indeed, nearly two-thirds of all research participants assessed many PR tools – both new and traditional – to be effective during launch and brand-building years.

These and other insights are now available in our report, "Public Relations Excellence: Using PR to Launch, Grow and Extend Your Brands."  Additional findings from this study include insights into what Public Relations channels, tactics and calls-to-action are most effective for reaching consumers of pharmaceutical products.  In addition, the report contains three case studies highlighting successfully employed Public Relations tactics at different lifecycle stages for three different products.

To download a complimentary summary containing insights found in this report, click on the following link: http://www3.best-in-class.com/re1111.htm.

In a benchmarking study that included 18 leading global pharmaceutical and biotech organizations, many key topics are examined, including:

  • PR strategies and tactics that are most effective at different lifecycle stages
  • PR tools and calls to action that are most effective
  • Case studies that reveal effective PR practices
  • Web site resources that are most effective for consumers
  • Lessons learned and best practices

For more information, contact Cameron Tew, Executive Director of Research and Publishing at Best Practices, LLC at (919) 767-9246 or ctew@best-in-class.com.

BEST PRACTICES, LLC conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for more than 17 years; our clients include 48 of the top 50 pharmaceutical companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research
2. Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems
3. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
4. Doctors in the US and Netherlands Using Fast RapidArc Radiotherapy Technology to Help Fight Cancer are Now Treating Tumors of the Head and Neck
5. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
6. Using living cells as nanotechnology factories
7. Researchers write protein nanoarrays using a fountain pen and electric fields
8. Edmonton's Technology Community: Using Social Media to Raise Awareness
9. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
10. RainDance Technologies to Present Sequence Enrichment Using Droplet-Based Microfluidics Workshop at ASHG 2008
11. RainDance Technologies to Present Workshop on Sequence Enrichment Using Innovative Microdroplet-Based Solutions at ASHG 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 3, 2016 The ... Discovery, Gene Expression) Lab-on-a-chip (IVD & POC, ... Diagnostics Centers), Fabrication Technology (Microarrays, Microfluidics) - ... market is expected to reach USD 17.75 ... in 2015, growing at a CAGR of ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... development, skill-building and compliance training platform on mobile devices, today released a new ... Regulatory Requirements for Medical Devices. The course is essential for owners or operators ...
(Date:5/3/2016)... MA (PRWEB) , ... May 03, 2016 , ... In ... number 25 out of the state’s 76 fastest-growing private companies; a small percentage of ... Massachusetts, and ranked organizations on the percent change in revenue from 2012 to 2015. ...
(Date:5/3/2016)... ... May 03, 2016 , ... Leading CEOs from biotech, ... 31st and June 1st at The Four Seasons Hotel Boston. , The Boston ... sciences, offering exclusive access to key decision makers who influence deal making and ...
Breaking Biology Technology:
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
Breaking Biology News(10 mins):